In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China’s SystImmune in a deal that could swell to $8.4 billion. It gives BMS ...
Ibotta (NYSE: IBTA) landed at No. 10 on the PitchBook list. Ahead of it were companies like SystImmune Inc., a Redmund, Washington-based biotechnology company with an $8.4 billion exit via an ...
Seattle-area biotech company SystImmune named Dr. Jie D’Elia as CEO. D’Elia previously was a senior vice president at Bristol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback